Viridian Therapeutics Inc Ordinary Shares VRDN 深 沪
已收盘 12-19 16:00:00 美东时间
31.92
+0.320
+1.01%
华盛通- 最 高32.88
- 今 开31.66
- 成交量 476.87万股
- 最 低 31.63
- 昨 收 31.60
- 总市值 30.47亿
- 52周最高 34.04
- 市盈率 静 --
- 换手率 5.00%
- 52周最低 9.90
- 委 比 78.71%
- 总股本 9544.20万
- 历史最高 270.00
- 量 比 3.20
- 振 幅 3.96%
- 历史最低 4.665
- 每 手 1
- 风险率 5.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Argenx Halts Phase 3 Thyroid Eye Disease Trial, Peers Like Viridian Therapeutics To Benefit
Argenx discontinues its Phase 3 UplighTED trial in thyroid eye disease after an interim futility review, while analysts maintain confidence in Vyvgart's broader growth.
12-15 23:25
美股大行评级 | 超配！大摩上调回声星通信评级；汽车地带、CBRL、金宝汤、家得宝等遭多家大行下调目标价
今日重点评级关注：Ascendiant Capital：维持Lucid Diagnostics"买入"评级，目标价从8美元升至8.25美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从12.5美元升至13美元
12-11 10:33
Analyst Says Viridian's New Thyroid Eye Drug Could Outperform Amgen's Tepezza
William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA review and VRDN-003 Phase 3 data.
12-04 04:25
William Blair Initiates Coverage On Viridian Therapeutics with Outperform Rating
William Blair analyst Lachlan Brown initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Outperform rating.
12-03 22:31
美股大行评级 | 摩根大通上调百度至"超配"，目标价升至188美元！Navan获多家机构首予"买入"评级，目标价最高30美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从4美元升至9美元；BTIG：维持Cullinan Therapeutics"买入"评级，目标价从32美元升至38美元
11-25 10:27
Truist Financial Initiates a Buy Rating on Viridian Therapeutics (VRDN)
Viridian Therapeutics received a Buy rating and price target from Truist Financ...
11-24 20:26
Viridian Therapeutics Advances Toward Profitability with Strategic Moves
Viridian Therapeutics, Inc. ( ($VRDN) ) has released its Q3 earnings. Here is a...
11-07 14:53
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
H.C. Wainwright Keeps Their Buy Rating on Viridian Therapeutics (VRDN)
In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Buy ...
11-06 00:16
Viridian Therapeutics Q3 EPS $(0.34) Beats $(0.98) Estimate, Sales $70.570K Beat $33.909K Estimate
Viridian Therapeutics (NASDAQ:VRDN) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.98) by 65.48 percent. This is a 61.36 percent increase over losses of $(0.88) per share
11-05 20:25
